mRNA vaccine trial reveals durable efficacy in pancreatic cancer treatment (nbcnews.com)

• Durable T-cell activation observed in clinical subjects.
• Significant potential for preventing cancer recurrence.
• Validation of neoantigen-targeted mRNA platforms.

"An early-stage clinical trial demonstrates that personalized mRNA vaccines can induce durable immune responses in pancreatic cancer patients. By targeting tumor-specific neoantigens, the vaccine trains the immune system to recognize and eliminate residual cancer cells. The data shows prolonged disease-free survival in participants, marking a significant advancement in therapeutic oncology. This progress underscores the strategic importance of European investments in synthetic biology and genomic medicine, essential for enhancing medical resilience and reducing dependence on foreign pharmaceutical advancements."